Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of $1.20, $0.13 better than the analyst estimate of $1.07. Revenue for the quarter came in at $515.3 million versus the consensus estimate of $512.36 million.

GUIDANCE

INGREZZA Net Product Sales of $2,100- $2,200M

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.